Investigational New Drugs

, 26:553 | Cite as

Phase Ι trial of weekly Docetaxel and daily Temozolomide in patients with metastatic disease

  • I. TamaskarEmail author
  • T. Mekhail
  • R. Dreicer
  • T. Olencki
  • S. Roman
  • P. Elson
  • R. M. Bukowski


Docetaxel is second generation taxoid that has shown activity against a variety of cancers and has been approved for use in cancers of the breast, lung, head and neck, ovaries and prostate. Temozolomide is an alkylating agent which crosses the blood brain barrier and has demonstrated antitumor activity against a broad range of tumor types, including malignant glioma, melanoma, non small cell lung cancer and carcinoma of the ovary and colon. A Phase I trial was conducted to determine the toxicity of this combination in refractory solid tumor patients. Methods: Twenty five patients with metastatic cancers were enrolled in a Phase I dose escalation trial. Docetaxel was administered weekly in 5 escalating doses of 25 to 35 mg/ m2 as a one-hour bolus intravenous infusion for 3 consecutive weeks. Temozolamide was administered orally daily for 3 weeks (escalating doses of 75 to 100 mg/m2). Cycles were repeated at 4 week intervals. Results: The maximum tolerated dose (MTD) was not determined in this study. The most commonly reported adverse events were mild to moderate nausea, vomiting and fatigue. Thrombocytopenia was the most commonly observed grade 3 and 4 hematological toxicity. Eight patients had dose interruptions for adverse events and only one patient had a dose reduction while receiving 30 mg/ m2 of docetaxel and 90 mg/ m2 of temozolomide due to grade 3 thrombocytopenia. Two patients achieved partial responses and 88% of the patients are deceased. The median survival is 8.4 months. Conclusions: The combination of docetaxel and temozolomide was well tolerated and these agents can be safely combined. For phase II trials, docetaxel 35 mg/ m2 IV day 1, 8 and 15, and daily temozolomide at 100 mg/ m2 day 1–21 are recommended.


Phase I trial Docetaxel and Temozolomide 


  1. 1.
    Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F (1991) Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51:4845–4852PubMedGoogle Scholar
  2. 2.
    Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332:1004–1014 doi: 10.1056/NEJM199504133321507 PubMedCrossRefGoogle Scholar
  3. 3.
    Riou J-F, Petitgenet O, Combeau C, Lavelle F (1994) Cellular uptake and efflux of docetaxel (Taxotere®) and paclitaxel (Taxol®) in P388 cell line. Proc Am Assoc Cancer Res 35:385Google Scholar
  4. 4.
    Taxotere package insertGoogle Scholar
  5. 5.
    Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS et al (1992) Phase I trial of temozolomide (CCRG 81045: M and B 39831: NSC 362856). Br J Cancer 65:287–291PubMedGoogle Scholar
  6. 6.
    Stevens MF, Hickman JA, Langdon SP, Chubb D, Vickers L, Stone R et al (1987) Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M and B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 47:5846–5852PubMedGoogle Scholar
  7. 7.
    Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35–61 doi: 10.1016/S0305-7372(97)90019-0 PubMedCrossRefGoogle Scholar
  8. 8.
    Baker SD, Wirth M, Statkevich P, Reidenberg P, Alton K, Sartorius SE et al (1999) Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5:309–317PubMedGoogle Scholar
  9. 9.
    Patel M, McCully C, Godwin K, Balis FM (2003) Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. J Neurooncol 61:203–207 doi: 10.1023/A:1022592913323 PubMedCrossRefGoogle Scholar
  10. 10.
    Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal brain tumor group. J Clin Oncol 17:2762–2771PubMedGoogle Scholar
  11. 11.
    Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593 doi: 10.1054/bjoc.2000.1316 PubMedCrossRefGoogle Scholar
  12. 12.
    Bleehen NM, Newlands ES, Lee SM, Thatcher N, Selby P, Calvert AH et al (1995) Cancer research campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 13:910–913PubMedGoogle Scholar
  13. 13.
    Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S et al (2000) Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 18:158–166PubMedGoogle Scholar
  14. 14.
    Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES (1997) In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 8:92–97 doi: 10.1097/00001813-199701000-00013 PubMedCrossRefGoogle Scholar
  15. 15.
    Adonizio CS, Babb JS, Maiale C, Huang C, Donahue J, Millenson MM et al (2002) Temozolomide in non-small-cell lung cancer: preliminary results of a phase II trial in previously treated patients. Clin Lung Cancer 3:254–258PubMedCrossRefGoogle Scholar
  16. 16.
    Christodoulou C, Bafaloukos D, Linardou H, Aravantinos G, Bamias A, Carina M et al (2005) Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a hellenic cooperative oncology group (HeCOG) phase II study. J Neurooncol 71:61–65 doi: 10.1007/s11060-004-9176-0 PubMedCrossRefGoogle Scholar
  17. 17.
    Bafaloukos D, Gogas H, Georgoulias V, Briassoulis E, Fountzilas G, Samantas E et al (2002) Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the hellenic cooperative oncology group. J Clin Oncol 20:420–425 doi: 10.1200/JCO.20.2.420 PubMedCrossRefGoogle Scholar
  18. 18.
    Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P et al (1999) Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81:1022–1030 doi: 10.1038/sj.bjc.6690802 PubMedCrossRefGoogle Scholar
  19. 19.
    Giannakakis T, Ziras N, Kakolyris S, Mavroudis D, Androulakis N, Agelaki S et al (2000) Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study. Eur J Cancer 36:742–747 doi: 10.1016/S0959-8049(00)00005-8 PubMedCrossRefGoogle Scholar
  20. 20.
    Rein DT, Kurbacher CM, Breidenbach M, Schondorf T, Schmidt T, Konig E et al (2002) Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study. Gynecol Oncol 87:98–103 doi: 10.1006/gyno.2002.6786 PubMedCrossRefGoogle Scholar
  21. 21.
    Hill BT, Whelan RDH, Shellard SA (1994) Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 12:169–182 doi: 10.1007/BF00873957 PubMedCrossRefGoogle Scholar
  22. 22.
    Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095–2103PubMedGoogle Scholar
  23. 23.
    Di Maio M, Perrone F, Chiodini P, Gallo C, Camps C, Schuette W et al (2007) Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 25:1377–1382 doi: 10.1200/JCO.2006.09.8251 PubMedCrossRefGoogle Scholar
  24. 24.
    Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW et al (2005) Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23:8389–8395 doi: 10.1200/JCO.2005.02.3739 PubMedCrossRefGoogle Scholar
  25. 25.
    Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F et al (2005) Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC). Ann Oncol 16:90–96 doi: 10.1093/annonc/mdi018 PubMedCrossRefGoogle Scholar
  26. 26.
    Gridelli C, Gallo C, Di Maio M, Barletta E, Illiano A, Maione P et al (2004) A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. the DISTAL 01 study. Br J Cancer 91:1996–2004 doi: 10.1038/sj.bjc.6602241 PubMedCrossRefGoogle Scholar
  27. 27.
    Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A et al (2008) Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112:1455–1461PubMedCrossRefGoogle Scholar
  28. 28.
    Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R et al (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18:1212–1219PubMedGoogle Scholar
  29. 29.
    Loffler TM (1998) Is there a place for “dose-dense” weekly schedules of the taxoids? Semin Oncol 25:32–34PubMedGoogle Scholar
  30. 30.
    Dhodapkar M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC et al (1997) Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer. Clin Cancer Res 3:1093–1100PubMedGoogle Scholar
  31. 31.
    Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I et al (1998) Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 58:4363–4367PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • I. Tamaskar
    • 1
    • 3
    Email author
  • T. Mekhail
    • 1
  • R. Dreicer
    • 1
  • T. Olencki
    • 2
  • S. Roman
    • 1
  • P. Elson
    • 1
  • R. M. Bukowski
    • 1
  1. 1.Department of Solid Tumor OncologyCleveland Clinic Taussig Cancer CenterClevelandUSA
  2. 2.Department of Hematology and OncologyOhio State UniversityColumbusUSA
  3. 3.Experimental Therapeutic Program, Cleveland Clinic Taussig Cancer CenterClevelandUSA

Personalised recommendations